WO2015187733A3 - Myostatin inhibitors for treatment of diabetes - Google Patents

Myostatin inhibitors for treatment of diabetes Download PDF

Info

Publication number
WO2015187733A3
WO2015187733A3 PCT/US2015/033835 US2015033835W WO2015187733A3 WO 2015187733 A3 WO2015187733 A3 WO 2015187733A3 US 2015033835 W US2015033835 W US 2015033835W WO 2015187733 A3 WO2015187733 A3 WO 2015187733A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
treatment
myostatin inhibitors
myostatin
inhibitors
Prior art date
Application number
PCT/US2015/033835
Other languages
French (fr)
Other versions
WO2015187733A2 (en
Inventor
Christopher Michael HAQQ
Original Assignee
Pinta Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinta Biotherapeutics, Inc. filed Critical Pinta Biotherapeutics, Inc.
Publication of WO2015187733A2 publication Critical patent/WO2015187733A2/en
Publication of WO2015187733A3 publication Critical patent/WO2015187733A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are methods of treating or modulating diabetes in an ESRD patient by administration of a Pinta (745) myostatin antagonist.
PCT/US2015/033835 2014-06-02 2015-06-02 Myostatin inhibitors for treatment of diabetes WO2015187733A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462006780P 2014-06-02 2014-06-02
US62/006,780 2014-06-02

Publications (2)

Publication Number Publication Date
WO2015187733A2 WO2015187733A2 (en) 2015-12-10
WO2015187733A3 true WO2015187733A3 (en) 2016-02-04

Family

ID=54767567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/033835 WO2015187733A2 (en) 2014-06-02 2015-06-02 Myostatin inhibitors for treatment of diabetes

Country Status (1)

Country Link
WO (1) WO2015187733A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140934A1 (en) * 2004-09-24 2006-06-29 Colin Gegg Modified Fc molecules
WO2007067616A2 (en) * 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140934A1 (en) * 2004-09-24 2006-06-29 Colin Gegg Modified Fc molecules
WO2007067616A2 (en) * 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"BIOCENTURY BCIQ: BioCentury Online Intelligence: PINTA 745 (formerly AMG 745)..", 27 August 2015 (2015-08-27), Retrieved from the Internet <URL:http://www.biocentury.com/products/pinta_745> *
"Clinical Trials.gov: Archive: Clinical Trials Identifier: NCT01958970. A Randomized, Double-Blind, Pilot Study Of PINTA 745, An Anti-Myostatin Peptibody", PATIENTS WITH END STAGE RENAL DISEASE WHO REQUIRE MAINTENANCE HEMODIALYSIS AND HAVE PROTEIN ENGERGY WASTING., 27 August 2015 (2015-08-27), Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01958970/2013_10_08> *

Also Published As

Publication number Publication date
WO2015187733A2 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
GB2544906B (en) Devices for treating vestibular and other medical impairments.
PT3506931T (en) Methods for preventing or treating allergy by administering an il-4r antagonist
EP3104807B8 (en) Device for teeth treatment
EP3131515A4 (en) Devices for therapeutic vascular procedures
GB2541571A (en) Pharmaceutical compositions
DK3171929T3 (en) DOSAGE FOR NERVE STIMULATION
EP3171786A4 (en) Devices and methods for treating heart failure
PT3110848T (en) Methods for treating skin infection by administering an il-4r antagonist
SG11201606649WA (en) Implantable medical device
EP3170467A4 (en) Ultrasonic vibrator for medical treatment
EP3221003A4 (en) Therapy system for transcutaneous in-vivo tissue engineering
EP3085410A4 (en) Skin treatment device using needle
HK1215864A1 (en) Cannula for catgut-embedding therapy
EA201791454A1 (en) DRUG FORMS FOR TRANSDERMAL ADMINISTRATION
EP3263152A4 (en) Medical treatment device
EP3226899A4 (en) Methods for treating dry eye disease by administering an il-6r antagonist
EP3122415A4 (en) Implantable medical devices
SG11201608257RA (en) A device for a medical treatment of a sclera
EP3263155A4 (en) Drug solution administering device
SI3148492T1 (en) Laser therapeutic device for ophthalmology
EA201692534A1 (en) METHODS OF TREATMENT OF HYPOTHONY
SG11201705194XA (en) Pharmaceutical composition for treating diabetes
EP3233081A4 (en) Transdermal drug delivery device including fentanyl
EP2992807A4 (en) Operating device for medical apparatus
PH12017500602A1 (en) Methods for treating ocular conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15803854

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15803854

Country of ref document: EP

Kind code of ref document: A2